The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.

Department of Neurology, VU University Medical Center, P.O. Box 7057, MB Amsterdam 1007, The Netherlands.
European Journal of Cancer (Impact Factor: 4.82). 06/2005; 41(8):1135-9. DOI: 10.1016/j.ejca.2005.02.012
Source: PubMed

ABSTRACT Chemotherapy-induced peripheral neuropathy (CIPN) is a common phenomenon, often resulting in serious limitations in daily functioning and compromised quality of life. Currently available toxicity grading systems typically use a combination of clinical and paraclinical parameters and relies on the judgment of clinicians and/or nurses. However, because many of the symptoms of CIPN are subjective in nature, it is only logical that an assessment of CIPN be based, at least in part, on patient self-report data. We report on the development of a patient self-report questionnaire, the CIPN20, intended to supplement the core quality of life questionnaire of the European Organization for Research and Treatment of Cancer (EORTC). Following EORTC guidelines, relevant CIPN-related issues were identified from a literature survey and interviews with health professionals (n=15) and patients (n=112). The resulting 20-item questionnaire was pre-tested in three languages and four countries and is currently being examined in a large, international clinical trial. The EORTC CIPN20 should provide valuable information on CIPN-related symptoms and functional limitations of patients exposed to potentially neurotoxic chemotherapeutic and/or neuroprotective agents.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluates persistence and severity of docetaxel-induced neuropathy (peripheral neuropathy (PN)) and impact on health related quality of life in survivors from early-stage breast cancer. One thousand and thirty-one patients with early-stage breast cancer, who received at least one cycle of docetaxel and provided information on PN during treatment, completed questionnaires on PN as an outcome (Common Toxicity Criteria (CTC) scores, European Organisation for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC CIPN20) and EORTC Quality of Life Questionnaire (QLQ)-C30) after 1-3years. Upon completion of docetaxel treatment, 241 patients (23%) reported PN, grades 2-4. PN persisted for 1-3years among 81 (34%) while PN regressed to grades 0-1 among 160 (66%). Among 790 patients (77%) without PN, 76 (10%) developed PN 1-3years later while 714 (90%) stayed free from PN. Significant risk factors for persistent PN were age ⩾55 (p=0.001), maximum grade of PN during docetaxel treatment (p<0.0001), persistent muscle and joint pain (p<0.0001), stomatitis (p=0.047) and fatigue (p=0.001). Persistent PN had a significant negative correlation with health-related quality of life (HRQOL), functional scales and symptom scales. Overall, 15% of breast cancer survivors treated with docetaxel report PN 1-3years after treatment with a significant negative impact on HRQOL. Copyright © 2014 Elsevier Ltd. All rights reserved.
    European journal of cancer (Oxford, England: 1990) 12/2014; 51(3). DOI:10.1016/j.ejca.2014.11.024 · 4.82 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this traineeship was to develop the academic, clinical, and research skills of an expert advanced practice nurse within the context of a mentor's funded program of research on the Cognitive Effects of Chemotherapy. The scope of the program was to support the trainee's doctoral education with an ultimate career goal of becoming a Clinical Breast Cancer Research Scientist through a mentored research experience. Ms. Bakitas expanded an established research program on CNS effects by developing a parallel focus on the peripheral nervous system effects of chemotherapy on quality of life. The major achievements of this final report, are the successful accomplishment of the planned training activities/tasks through the completion of the doctoral degree through successful defense of the dissertation, abstract presentations, acquiring an ACS doctoral scholarship, and receiving the Anthony DiGuida Research Prize for the dissertation. The significance of these achievements is that this funding has supported the training of a clinical nurse expert in a foundation for conduct of clinical breast cancer research.